Laberon (Beclometasone Dipropionate, Formoterol Fumarate Dihydrate)

Laberon is used in the respiratory disease pathway to provide long‑term control of airway obstruction.

• Asthma: reduces frequency of symptoms and exacerbations.
• Chronic obstructive pulmonary disease (COPD): improves lung function and decreases breathlessness.
• Bronchial hyperresponsiveness: decreases airway inflammation and improves responsiveness to triggers.

• Beclometasone dipropionate binds to intracellular glucocorticoid receptors, modulating gene transcription to suppress inflammatory cytokines, reduce eosinophil activity and restore epithelial integrity. Formoterol fumarate selectively stimulates β2‑adrenergic receptors on bronchial smooth muscle, increasing cyclic AMP and causing prolonged relaxation of airway smooth muscle, thereby enhancing airflow. This synergy allows once‑daily maintenance therapy with rapid onset of bronchodilation.

The most frequently reported adverse reactions with Laberon are related to its local and systemic pharmacology.

Common Side Effects

• Throat irritation or soreness.
• Hoarseness or voice changes.
• Cough during or after inhalation.
• Oral candidiasis (fungal infection).
• Headache.
• Tremor.

Serious or Rare Side Effects

• Paradoxical bronchospasm.
• Adrenal suppression with prolonged high‑dose use.
• Severe allergic reactions (anaphylaxis, angioedema).
• Pneumonia or respiratory infections.
• Cardiac arrhythmias.
• Hyperglycaemia in susceptible patients.

When prescribing Laberon, clinicians should consider several safety aspects.

• Assess disease control: ensure patient is stable before initiating therapy.
• Monitor for COPD exacerbations: adjust treatment if symptoms worsen.
• Use a spacer device: reduces oropharyngeal deposition and irritation.
• Avoid abrupt discontinuation: taper if long‑term high‑dose therapy is required.
• Review concomitant medications: consider potential additive effects on heart rate or blood glucose.
• Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Laberon may interact with other medicines that affect the respiratory or cardiovascular systems.

Major Interactions (Avoid)

• Non‑selective β‑blockers: can diminish bronchodilator effect and precipitate bronchospasm.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase systemic steroid exposure.
• Diuretics (e.g., furosemide) in high doses: can enhance risk of hypokalaemia and cardiac effects.

Moderate Interactions (Monitor Closely)

• Theophylline: may increase risk of tachycardia and tremor.
• Anticholinergic bronchodilators: additive bronchodilation may require dose adjustment.
• Monoamine oxidase inhibitors (MAOIs): monitor for possible cardiovascular effects.